 |
|
|
|
 |
|
|
| Article 1 to 10 out of 41 concerning Affymetrix Inc.
|
-
Roche NimbleGen and Affymetrix Expand Licensing Agreement
(17 Mar 2008)
Roche NimbleGen Inc., a company of Roche Applied Science, and Affymetrix Inc. announced that they have expanded the terms of the license to a number of Affymetrix patents originally granted in October 2006. The expanded license now provides certain ...
-
Affymetrix and Illumina Settle Their Patent Disputes
(15 Jan 2008)
Affymetrix, Inc. and Illumina, Inc. announced that they have entered into a settlement agreement to resolve their patent litigation. Under the terms of the settlement, Illumina agreed, without admitting liability, to make a one-time payment to ...
-
Affymetrix and Empire Genomics Enter Into Licensing Agreement
(11 Sep 2007)
Affymetrix Inc. announced that Empire Genomics, LLC, has obtained a non-exclusive, worldwide license to a number of Affymetrix patents covering the manufacturing, use and sales of nucleic acid microarrays and related products and services for ...
-
Affymetrix Launches European Cytogenetic Research Initiative
(11 Jul 2007)
Affymetrix Inc. announced the launch of the European Cytogenetic Research Initiative, a collaboration between Affymetrix, the University of Nijmegen in the Netherlands, the University of Tuebingen in Germany and the NHS Regional Genetics Laboratory ...
-
Affymetrix Selects Singapore For Its First Manufacturing Facility Outside The United States
(24 May 2007)
Affymetrix Inc. officially opened its manufacturing facility in Singapore. The new state-of-the-art building is Affymetrix's first manufacturing facility outside of the United States of America, enabling the company to better serve and support its ...
-
Affymetrix Launches Program to Advance Cancer Research
(19 Apr 2007)
Partnership With Leading Scientists Aims to Accelerate Breakthroughs in More Than 10 Types of Cancers
Affymetrix Inc. announced the launch of the Collaborations in Cancer Research Program, an alliance between Affymetrix and up to 30 leading European cancer researchers. As part of the program, Affymetrix will partially fund selected research projects ...
-
Affymetrix Signs Three-Year Translational Medicine Agreement With Vanderbilt-Ingram Cancer Center
(26 Jan 2007)
Research Team to Use Affymetrix GeneChip(R) Technology to Develop Applications for Cancer and HIV/AIDS
Affymetrix Inc. and Vanderbilt-Ingram Cancer Center announced that they have entered into a three-year translational research collaboration to analyze genomic information across a large number of patient samples. Under terms of the agreement, ...
-
Affymetrix Names Kevin King President of Life Sciences Business
(21 Dec 2006)
Affymetrix Inc. announced that it has appointed Kevin M. King to president of life sciences business and executive vice president, reporting to Stephen P.A. Fodor, Ph.D., chairman and CEO. King previously served as president and CEO of Thomson ...
-
Scan of Entire Human Genome Finds Unexpected New Clues on Lou Gehrig's Disease
(04 Dec 2006)
A comprehensive scan of the human genome has identified more than 50 genetic abnormalities in people with sporadic amyotrophic lateral sclerosis (ALS, or Lou Gehrig's disease), the Muscular Dystrophy Association (MDA) and the Translational Genomics ...
-
Wyeth Extends Agreement with Affymetrix to 15 Years
(26 Oct 2006)
Affymetrix Inc. announced that Wyeth has signed another agreement with Affymetrix to use GeneChip(R) microarray technology for three more years, further extending the relationship that began in 1994. Under the agreement, Wyeth will continue to apply ...
Additional information
Affymetrix Inc.
Santa Clara, CA, USA
Company
|
|
|
|
|
|
Top
